- Home
- LAB vs VALN Comparison
LAB vs VALN Comparison
Compare LAB & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- VALN
- Stock Information
- Founded
- LAB 1999
- VALN 2012
- Country
- LAB United States
- VALN France
- Employees
- LAB N/A
- VALN N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LAB Industrials
- VALN Health Care
- Exchange
- LAB Nasdaq
- VALN Nasdaq
- Market Cap
- LAB 435.8M
- VALN 510.7M
- IPO Year
- LAB 2011
- VALN 2021
- Fundamental
- Price
- LAB $1.24
- VALN $6.98
- Analyst Decision
- LAB Buy
- VALN Strong Buy
- Analyst Count
- LAB 2
- VALN 2
- Target Price
- LAB $2.50
- VALN $16.00
- AVG Volume (30 Days)
- LAB 1.2M
- VALN 140.3K
- Earning Date
- LAB 05-06-2025
- VALN 05-06-2025
- Dividend Yield
- LAB N/A
- VALN N/A
- EPS Growth
- LAB N/A
- VALN N/A
- EPS
- LAB N/A
- VALN N/A
- Revenue
- LAB $174,432,000.00
- VALN $175,564,758.00
- Revenue This Year
- LAB N/A
- VALN $19.17
- Revenue Next Year
- LAB $12.77
- VALN $26.31
- P/E Ratio
- LAB N/A
- VALN N/A
- Revenue Growth
- LAB 64.03
- VALN 10.32
- 52 Week Low
- LAB $0.97
- VALN $3.62
- 52 Week High
- LAB $2.74
- VALN $9.50
- Technical
- Relative Strength Index (RSI)
- LAB 56.32
- VALN 53.19
- Support Level
- LAB $0.99
- VALN $6.59
- Resistance Level
- LAB $1.18
- VALN $7.05
- Average True Range (ATR)
- LAB 0.09
- VALN 0.47
- MACD
- LAB 0.02
- VALN 0.03
- Stochastic Oscillator
- LAB 75.00
- VALN 67.30
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.